Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.18
-0.24 (-1.12%)
At close: Feb 27, 2026, 4:00 PM EST
21.35
+0.17 (0.80%)
After-hours: Feb 27, 2026, 6:00 PM EST
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Denali Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $30.8, which forecasts a 45.42% increase in the stock price over the next year. The lowest target is $25 and the highest is $42.
Price Target: $30.8 (+45.42%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 7 | 7 | 5 |
| Buy | 8 | 8 | 7 | 7 | 6 | 6 |
| Hold | 1 | 1 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 13 | 14 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Feb 24, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +51.09% | Feb 6, 2026 |
| UBS | UBS | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +18.04% | Jan 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $31 → $30 | Buy | Maintains | $31 → $30 | +41.64% | Dec 11, 2025 |
| Wedbush | Wedbush | Buy Maintains $30 → $31 | Buy | Maintains | $30 → $31 | +46.36% | Dec 5, 2025 |
Financial Forecast
Revenue This Year
43.57M
Revenue Next Year
157.94M
from 43.57M
Increased by 262.52%
EPS This Year
-3.04
from -2.97
EPS Next Year
-2.75
from -3.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 167.8M | 368.5M | |||
| Avg | 43.6M | 157.9M | |||
| Low | 7.0M | 41.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 745.8% | |||
| Avg | - | 262.5% | |||
| Low | - | -5.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.09 | -2.12 | |||
| Avg | -3.04 | -2.75 | |||
| Low | -3.62 | -3.46 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.